Display options
Cite
Lee MS, Kim YH, Lee BR, et al. Novel antidepressant-like activity of caffeic Acid phenethyl ester is mediated by enhanced glucocorticoid receptor function in the hippocampus. Evid Based Complement Alternat Med. 2014;2014:646039doi: 10.1155/2014/646039.
Lee, M. S., Kim, Y. H., Lee, B. R., Kwon, S. H., Moon, W. J., Hong, K. S., Song, Y. S., Morita, K., Hahm, D. H., Shim, I., & Her, S. (2014). Novel antidepressant-like activity of caffeic Acid phenethyl ester is mediated by enhanced glucocorticoid receptor function in the hippocampus. Evidence-based complementary and alternative medicine : eCAM, 2014646039. https://doi.org/10.1155/2014/646039
Lee, Mi-Sook, et al. "Novel antidepressant-like activity of caffeic Acid phenethyl ester is mediated by enhanced glucocorticoid receptor function in the hippocampus." Evidence-based complementary and alternative medicine : eCAM vol. 2014 (2014): 646039. doi: https://doi.org/10.1155/2014/646039
Lee MS, Kim YH, Lee BR, Kwon SH, Moon WJ, Hong KS, Song YS, Morita K, Hahm DH, Shim I, Her S. Novel antidepressant-like activity of caffeic Acid phenethyl ester is mediated by enhanced glucocorticoid receptor function in the hippocampus. Evid Based Complement Alternat Med. 2014;2014:646039. doi: 10.1155/2014/646039. Epub 2014 Nov 16. PMID: 25477995; PMCID: PMC4248557.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2014;2014:646039. doi: 10.1155/2014/646039. Epub 2014 Nov 16.

Novel antidepressant-like activity of caffeic Acid phenethyl ester is mediated by enhanced glucocorticoid receptor function in the hippocampus.

Evidence-based complementary and alternative medicine : eCAM

Mi-Sook Lee, Young Han Kim, Bo-Ram Lee, Seung-Hae Kwon, Won-Jin Moon, Kwan-Su Hong, Yun Seon Song, Kyoji Morita, Dae Hyun Hahm, Insop Shim, Song Her

Affiliations

  1. Division of Bio-Imaging, Chuncheon Center, Korea Basic Science Institute, Chuncheon 200-701, Republic of Korea ; Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
  2. Division of Bio-Imaging, Chuncheon Center, Korea Basic Science Institute, Chuncheon 200-701, Republic of Korea.
  3. Gwangju Center, Korea Basic Science Institute, Gwangju 500-757, Republic of Korea.
  4. MR Research Center, Korea Basic Science Institute, Cheongwon 363-883, Republic of Korea.
  5. College of Pharmacy, Sookmyung Women's University, Seoul 140-742, Republic of Korea.
  6. Laboratory of Neuropharmacology, Department of Nursing, School of Health Sciences, Shikoku University, Tokushima 771-1192, Republic of Korea.
  7. Acupuncture & Meridian Science Research Center, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Japan.
  8. Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.

PMID: 25477995 PMCID: PMC4248557 DOI: 10.1155/2014/646039

Abstract

Caffeic acid phenethyl ester (CAPE) is an active component of propolis that has a variety of potential pharmacological effects. Although we previously demonstrated that propolis has antidepressant-like activity, the effect of CAPE on this activity remains unknown. The present study assessed whether treatment with CAPE (5, 10, and 20 µmol/kg for 21 days) has an antidepressant-like effect in mice subjected to chronic unpredictable stress via tail suspension (TST) and forced swim (FST) tests. CAPE administration induced behaviors consistent with an antidepressant effect, evidenced by decreased immobility in the TST and FST independent of any effect on serum corticosterone secretion. Western blots, conducted subsequent to behavioral assessment, revealed that CAPE significantly decreased glucocorticoid receptor phosphorylation at S234 (pGR(S234)), resulting in an increased pGR(S220/S234) ratio. We also observed negative correlations between pGR(S220)/(S234) and p38 mitogen-activated protein kinase (p38MAPK) phosphorylation, which was decreased by CAPE treatment. These findings suggest that CAPE treatment exerts an antidepressant-like effect via downregulation of p38MAPK phosphorylation, thereby contributing to enhanced GR function.

References

  1. Biomed Res Int. 2014;2014:145342 - PubMed
  2. Pharmacol Biochem Behav. 2001 Oct-Nov;70(2-3):187-92 - PubMed
  3. Mol Endocrinol. 2005 Jun;19(6):1569-83 - PubMed
  4. Behav Brain Res. 2004 Dec 6;155(2):291-9 - PubMed
  5. Mol Psychiatry. 2002;7(9):985-94, 924 - PubMed
  6. Psychoneuroendocrinology. 2009 Jul;34(6):822-32 - PubMed
  7. IUBMB Life. 2009 Oct;61(10):979-86 - PubMed
  8. Evid Based Complement Alternat Med. 2013;2013:217853 - PubMed
  9. J Endocrinol. 2009 Jul;202(1):87-97 - PubMed
  10. J Mol Histol. 2012 Feb;43(1):49-57 - PubMed
  11. Psychiatr Pol. 1996 Sep-Oct;30(5):741-55 - PubMed
  12. Clin Neuropathol. 2007 Mar-Apr;26(2):80-4 - PubMed
  13. Br J Pharmacol. 2012 Jun;166(3):1151-68 - PubMed
  14. Proc Natl Acad Sci U S A. 1984 Oct;81(19):6174-7 - PubMed
  15. J Biol Chem. 1999 Jan 8;274(2):1005-10 - PubMed
  16. Mol Pharmacol. 2009 Mar;75(3):704-12 - PubMed
  17. J Neurosci. 1996 Apr 1;16(7):2365-72 - PubMed
  18. BMB Rep. 2008 Mar 31;41(3):242-7 - PubMed
  19. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:281-5 - PubMed
  20. Metabolism. 2012 Nov;61(11):1606-14 - PubMed
  21. Eur J Neurosci. 2006 Oct;24(7):1850-6 - PubMed
  22. Psychopharmacology (Berl). 1985;85(3):367-70 - PubMed
  23. Mol Cell Biol. 1997 Jul;17(7):3947-54 - PubMed
  24. J Mol Neurosci. 2004;24(2):207-16 - PubMed
  25. J Neurosci. 2013 Aug 21;33(34):13673-85 - PubMed
  26. Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14629-34 - PubMed
  27. J Endocrinol. 1987 Dec;115(3):459-67 - PubMed
  28. J Neuroimmunol. 2003 Nov;144(1-2):53-60 - PubMed
  29. Psychiatr Pol. 2006 May-Jun;40(3):415-30 - PubMed
  30. Biol Psychiatry. 2001 Mar 1;49(5):391-404 - PubMed
  31. Behav Brain Res. 2013 Jan 1;236(1):56-61 - PubMed
  32. Drug Discov Today Ther Strateg. 2008 Fall;5(3):151-156 - PubMed
  33. J Neurochem. 2001 May;77(3):916-28 - PubMed
  34. Biochem Biophys Res Commun. 2010 Apr 2;394(2):348-53 - PubMed
  35. Brain Res. 2008 Mar 27;1201:135-42 - PubMed
  36. Psychopharmacology (Berl). 2005 Jan;177(3):245-55 - PubMed
  37. Life Sci. 2006 May 1;78(23):2758-62 - PubMed
  38. Ann N Y Acad Sci. 2004 Jun;1024:86-101 - PubMed
  39. Biochem Cell Biol. 2014 Aug;92(4):243-9 - PubMed
  40. Psychopharmacology (Berl). 2001 May;155(3):315-22 - PubMed
  41. Nat Neurosci. 2009 Mar;12(3):342-8 - PubMed
  42. Neuroscience. 2008 Mar 27;152(3):703-12 - PubMed
  43. Neuropharmacology. 2004 Dec;47(7):1062-9 - PubMed
  44. Neuropsychopharmacology. 2012 Nov;37(12 ):2671-83 - PubMed
  45. Psychoneuroendocrinology. 2011 Apr;36(3):415-25 - PubMed
  46. J Neurochem. 2005 Jun;93(6):1551-60 - PubMed
  47. Chin Med J (Engl). 2006 Jan 20;119(2):140-7 - PubMed
  48. J Affect Disord. 2012 Feb;136(3):558-66 - PubMed
  49. Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2050-5 - PubMed
  50. Neurosci Biobehav Rev. 2005;29(4-5):571-625 - PubMed
  51. J Affect Disord. 2001 Jan;62(1-2):77-91 - PubMed
  52. Evid Based Complement Alternat Med. 2005 Mar;2(1):29-32 - PubMed
  53. Neuroscience. 2008 Sep 9;155(4):1098-105 - PubMed

Publication Types